×
Daraxonrasib pancreatic cancer treatment — patient receiving chemotherapy infusion in an oncology centre

A new combination treatment built around the targeted drug daraxonrasib shrank or eliminated tumours in more than six in ten patients with advanced pancreatic cancer, according to results presented at a major cancer conference in Barcelona this week. In one in twelve patients, tumours disappeared entirely on scans.

FAKTA

  • 61 patients with metastatic pancreatic cancer received daraxonrasib plus chemotherapy as their first treatment.
  • Tumours shrank or disappeared in 60.7% of patients; 8.2% had complete responses, with no tumour visible on scans.
  • The treatment held the disease in check in 90.2% of patients; median progression-free survival was 12.8 months.
  • 76.6% of patients were still alive after 12 months.
  • The results were presented on 20 November 2026 at the EORTC-NCI-AACR symposium in Barcelona.

Deep Responses in a Hard-to-Treat Cancer

The findings come from the phase I/II RMC-GI-102 trial, in which patients whose pancreatic cancer had already spread received 200 milligrams of daraxonrasib as a daily pill, together with two standard chemotherapy drugs, gemcitabine and nab-paclitaxel, given by intravenous drip. The data covered patients treated up to 28 September 2026, with a median follow-up of 18.3 months.

Presenting the results, Dr Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York, said the combination produced deeper responses than doctors had seen before, with disease control lasting nearly twice as long as is typical with chemotherapy alone. Disease control lasted a median of 12.8 months, and more than three quarters of patients were alive at one year.

Targeting the Cancer’s Engine

Daraxonrasib works differently from older cancer drugs. It targets the RAS protein, a growth signal that drives most pancreatic tumours. More than 90% of pancreatic cancers carry a mutation in the KRAS gene, which keeps that signal switched on. The drug blocks the active form of RAS, cutting off the instructions that help cancer cells survive and multiply.

The drug, sold under the brand name RASONQUE, was approved by the United States Food and Drug Administration in August 2026 for patients whose cancer had already been treated. That approval followed a large phase III trial, RASolute 302, in which daraxonrasib nearly doubled median survival, to 13.2 months against 6.6 months with chemotherapy, in previously treated patients.

Cautious Optimism

Doctors stressed that the new results come from an early-phase study with no comparison group, so they cannot yet prove how much better the combination is than chemotherapy alone. Only 5% of patients stopped treatment because of side effects linked to daraxonrasib, and the drug was generally tolerated better than chemotherapy in the earlier large trial.

A larger randomised phase III trial, RASolute 303, is now under way to compare daraxonrasib, alone and combined with chemotherapy, directly against standard chemotherapy in newly diagnosed patients. Pancreatic cancer is often diagnosed only after it has spread, and survival rates remain among the lowest of any major cancer, so researchers say any treatment that deepens responses at the start of therapy could matter. More international coverage is available on Watan News.

Leave a Reply

Your email address will not be published. Required fields are marked *

Author

usmanch0013@gmail.com

Related Posts

Former Brazilian President Jair Bolsonaro outside a hospital in Brasilia

Bolsonaro in Intensive Care with Intestinal Obstruction

Former Brazilian President Jair Bolsonaro is in intensive care in Brasilia with an acute intestinal obstruction. The hospital says the 71-year-old is...

Read out all
Climate ambassador training workshop for university students in Egypt

Egyptian Institute Pitches 20-Country Climate Ambassador Network at COP31

Egypt’s Institute of Sustainability and Carbon Footprint pitched a 20-country climate ambassador network at COP31 in Antalya, targeting 20 countries, 20 academic...

Read out all
Earthshot Prize 2026 winners awards ceremony stage in Mumbai with green globe

Earthshot Prize 2026 Winners: Bhutan, Mahindra, Ørsted, Niue and PFAS-Free France Take £1 Million Each

Five winners were crowned at The Earthshot Prize 2026 in Mumbai on 17 November 2026: Bhutan, Mahindra Last Mile Mobility, Ørsted, Niue...

Read out all
Indonesia factory fire rescuers search burnt candy factory Serang Banten

Indonesia Factory Fire Kills 3 as Rescuers Search for 36 Missing Workers

Rescuers in Indonesia searched on Sunday for 36 workers missing after a fire at a candy factory in Serang, Banten, killed 3...

Read out all
Addis Ababa skyline at golden hour — the Ethiopian capital will host COP32 in November 2027

COP32 Heads to Addis Ababa as Ethiopia Sets Out Its Vision for 2027

COP32 will take place in Addis Ababa from 8 to 19 November 2027. Ethiopia's incoming presidency has set out three priorities —...

Read out all
Flags of the United States and Canada flying side by side

Trump Adviser Accuses Canada of Dishonesty in Trade Talks

White House trade adviser Peter Navarro accused Canada of “arrogance and dishonesty” in trade talks, warning Ottawa is misreading its position as...

Read out all